Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Department of Pharmacy Services, District Headquarters Hospital, Pakpattan, Pakistan.
Rev Soc Bras Med Trop. 2023 Jun 2;56:e0044. doi: 10.1590/0037-8682-0044-2023. eCollection 2023.
Safety and efficacy concerns regarding coronavirus disease 2019 (COVID-19) vaccines are common among the public and have a negative impact on their uptake. We aimed to report the adverse effects currently associated with the vaccine in Pakistan to build confidence among the population for its adoption.
A cross-sectional study was conducted in five districts of the Punjab province of Pakistan between January and March 2022. The participants were recruited using convenience sampling. All data were analyzed using SPSS 22.
We recruited 1622 people with the majority aged between 25-45 years. Of these, 51% were female, including 27 pregnant women and 42 lactating mothers. Most participants had received the Sinopharm (62.6%) or Sinovac (17.8%) vaccines. The incidences of at least one side effect after the first (N = 1622), second (N = 1484), and booster doses (N = 219) of the COVID-19 vaccine were 16.5%, 20.1%, and 32%, respectively. Inflammation/erythema at the injection site, pain at the injection site, fever, and bone/muscle pain were common side effects of vaccination. No significant differences were observed in the adverse effect scores between all demographic variables except for pregnancy (P = 0.012) after the initial dose. No significant association was observed between any variable and the side effect scores of the second and booster doses of the vaccine.
Our study showed a 16-32% prevalence of self-reported side effects after the first, second, and booster COVID-19 vaccinations. Most adverse effects were mild and transient, indicating the safety of different COVID-19 vaccines.
公众对 2019 年冠状病毒病(COVID-19)疫苗的安全性和疗效存在担忧,这对疫苗接种产生了负面影响。我们旨在报告目前与巴基斯坦疫苗相关的不良反应,以建立公众对其采用的信心。
本研究于 2022 年 1 月至 3 月在巴基斯坦旁遮普省的五个地区进行了一项横断面研究。使用便利抽样法招募参与者。所有数据均使用 SPSS 22 进行分析。
我们招募了 1622 人,其中大多数年龄在 25-45 岁之间。其中,51%为女性,包括 27 名孕妇和 42 名哺乳期妇女。大多数参与者接种了国药(62.6%)或科兴(17.8%)疫苗。首次(N=1622)、第二次(N=1484)和加强针(N=219)接种 COVID-19 疫苗后至少出现一种不良反应的发生率分别为 16.5%、20.1%和 32%。接种部位炎症/红斑、接种部位疼痛、发热和骨/肌肉疼痛是常见的疫苗不良反应。除初次接种后妊娠(P=0.012)外,所有人口统计学变量之间的不良反应评分无显著差异。未观察到任何变量与第二次和加强针疫苗的不良反应评分之间存在显著关联。
我们的研究显示,首次、第二次和加强针 COVID-19 疫苗接种后,自我报告的不良反应发生率为 16-32%。大多数不良反应为轻度和短暂的,表明不同 COVID-19 疫苗的安全性。